Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Gene TechnologyASX:BGT +4.55% EV-to-EBITDA is -2.27 as of Aug. 06, 2026. The stock has 2 warning signs investors should review. Among 411 Biotechnology companies, Bio-Gene Technology ranks worse than 243308.76% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bio-Gene Technology's enterprise value is A$7.70 Mil.
Bio-Gene Technology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.39 Mil. Therefore, Bio-Gene Technology's EV-to-EBITDA for today is -2.27.
The historical rank and industry rank for Bio-Gene Technology's EV-to-EBITDA or its related term are showing as below:
ASX:BGT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.73 Med: -3.59 Max: 0.1
Current: -2.27
During the past 8 years, the highest EV-to-EBITDA of Bio-Gene Technology was 0.10. The lowest was -15.73. And the median was -3.59.
ASX:BGT's EV-to-EBITDA is ranked worse than 100% of 411
companies
in the Biotechnology industry
Industry Median: 12.78
vs ASX:BGT: -2.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bio-Gene Technology's PE Ratio (TTM) for today is calculated as:
Bio-Gene Technology's share price for today is A$0.023.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bio-Gene Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bio-Gene Technology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BGT vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Bio-Gene Technology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Gene Technology EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bio-Gene Technology's EV-to-EBITDA falls into.
Bio-Gene Technology's current Enterprise Value is A$7.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bio-Gene Technology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Gene Technology (ASX:BGT) has a EV-to-EBITDA of -2.27 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bio-Gene Technology. According to the industry distribution chart, Bio-Gene Technology ranks #999999 out of 411 companies in the Biotechnology industry.
Is Bio-Gene Technology's EV-to-EBITDA too high?
Bio-Gene Technology's current EV-to-EBITDA is -2.27. Based on the distribution chart, Bio-Gene Technology ranks #999999 out of 411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Gene Technology's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Gene Technology ranks #999999 out of 411 companies for EV-to-EBITDA. This places Bio-Gene Technology in the lower half of its industry. The industry median EV-to-EBITDA is 12.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.78, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bio-Gene Technology. For the Biotechnology industry, the median EV-to-EBITDA is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Gene Technology's current EV-to-EBITDA is -2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current EV-to-EBITDA of -2.27. The current EV-to-EBITDA is -2.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current EV-to-EBITDA is -2.27 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BGT has been successfully added to your 
